 |
|
|
|
|
 |
Last Updated: Jun 21, 2009 - 2:12:59 AM |
Latest Research
:
Cancer
:
Colon
Alcohol, cigarettes can cause bowel cancer
Beware of alcohol and cigarettes, they can cause bowel cancer, says a new study.
Jun 22, 2009 - 11:12:04 AM
|
Latest Research
:
Cancer
:
Brain
Electronic nose potent new weapon against brain cancer
An electronic 'nose' developed by NASA for air quality monitoring on Space Shuttle Endeavour can also act as a potent new weapon against brain cancer.
Jun 18, 2009 - 1:23:51 PM
|
Latest Research
Dual role in breast tissue for a protein involved in leukemia
Washington, DC - A protein known to play a role in growth of some types of leukemia appears to have a mixed function in breast cancer development, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).
Jun 12, 2009 - 4:00:00 AM
|
Latest Research
Common chemotherapy drug triggers fatal allergic reactions
CHICAGO -- A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.
Jun 8, 2009 - 4:00:00 AM
|
Latest Research
Singapore scientists elected into National Academy of Sciences
Renowned Singapore-based cancer geneticists Neal Copeland, Ph.D., and Nancy Jenkins, Ph.D., who are among the top 50 most-cited biomedical scientists in the world today, have been elected into the prestigious National Academy of Sciences (NAS).
Jun 1, 2009 - 4:00:00 AM
|
Latest Research
I-SPY trial offers key insights into locally advanced breast cancer
Scientists are reporting two findings that could influence the way researchers screen for, treat and assess prognosis for women with locally advanced breast cancer, an aggressive form of the disease. One finding offers a critical message regarding treatment strategy, they say.
Jun 1, 2009 - 4:00:00 AM
|
Latest Research
Chemotherapy combination outcomes differ for aged, younger colon cancer patients
ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who will present their findings at the American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Fla.
May 29, 2009 - 4:00:00 AM
|
Latest Research
One in ten advanced colon cancer patients worry about prescription drug costs
ORLANDO, Fla.--The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. Although few patients reported substantial worry about drug costs, still fewer reported discussing drug cost issues with their physicians, suggesting there are opportunities for improving how physicians integrate discussions about drug costs into clinical practice.
May 29, 2009 - 4:00:00 AM
|
Latest Research
New blood test greatly reduces false-positives in prostate cancer screening
ORLANDO, Fla.--A new blood test used in combination with a conventional prostate-specific antigen (PSA) screening sharply increases the accuracy of prostate cancer diagnosis, and could eliminate tens of thousands of unneeded, painful, and costly prostate biopsies annually, according to a study led by researchers at Dana-Farber Cancer Institute.
May 28, 2009 - 4:00:00 AM
|
Latest Research
Lombardi scientist brings 'dream team' breast cancer research effort to GUMC
Washington, DC -- It's called a Dream Team. Lombardi Comprehensive Cancer Center's incoming scientific director V. Craig Jordan, OBE, PhD, DSc, and 12 of the nation's top breast cancer researchers have been awarded a multi-million dollar grant from Stand Up To Cancer (SU2C) to form a scientific Dream Team. This collaboration of the best and brightest scientists will conduct new breast cancer research with the goal of producing tangible research results benefiting patient care within three years.
May 27, 2009 - 4:00:00 AM
|
Latest Research
:
Cancer
:
Colon
TSPAN1 expression-a useful tool to evaluate prognosis in colorectal cancer
A research team led by Dr Jian-Wei Zhu from Nantong University, China, investigated the association between TSPAN1 and human colorectal adenocarcinoma.
May 24, 2009 - 10:38:30 AM
|
Latest Research
'Happy hour' gene discovery suggests cancer drugs might treat alcoholism
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role in controlling the insects' response to alcohol.
May 21, 2009 - 4:00:00 AM
|
Latest Research
NC State and UNC Lineberger collaborate to combat cancer
Chapel Hill, NC - What do a college of veterinary medicine and a cancer treatment and research center have in common? The answer may be as plain as the nose on your dog's face. Researchers from North Carolina State University's College of Veterinary Medicine and the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center are combining their expertise to pinpoint the cause of -- and improve treatments for -- non-Hodgkin lymphoma in human and canine patients.
May 19, 2009 - 4:00:00 AM
|
Latest Research
Quick test for prostate cancer
A new 3-minute test could help in diagnosing prostate cancer, the most common cancer in men in the UK, according to scientists.
May 18, 2009 - 4:00:00 AM
|
Latest Research
Survival predictors may help customize treatment options for men with metastatic prostate cancer
Four risk factors that help predict how long men may survive with metastatic prostate cancer could help doctors choose more effective treatments, according to a study led by researchers in the Duke Comprehensive Cancer Center.
May 14, 2009 - 4:00:00 AM
|
Latest Research
Worldwide success in treatment of liver tumors
Leicester consultant surgeon who has developed a pioneering technique using microwaves to destroy liver tumours has treated more than 100 patients in the UK and other patients are now being treated internationally.
May 12, 2009 - 4:00:00 AM
|
Latest Research
Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants
Over 50 research grants totaling $24 million in U.S. dollars have been awarded to Singapore universities, research institutes and hospitals to fund studies related to asthma and other immune system disorders, infectious diseases, aging and cancer.
Apr 28, 2009 - 4:00:00 AM
|
Latest Research
Survival rates for cancer rise across Ireland
Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report launched today reveals.
Apr 24, 2009 - 4:00:00 AM
|
Latest Research
Vitamin K with sorafenib showed anti-tumor effects in pancreas cancer, hepatocellular carcinoma
(PHILADELPHIA) A combination of sorafenib and vitamin K had an effect in vitro on both human pancreas cancer and hepatocellular carcinoma, according to researchers from the Kimmel Cancer Center at Jefferson. Data from the two studies were presented at the AACR 100th Annual Meeting 2009 in Denver. (Abstract #5470 and #5483)
Apr 22, 2009 - 4:00:00 AM
|
Latest Research
Instead of fighting breast cancer, immune cell promotes its spread
Researchers at the UC San Diego School of Medicine and the Moores UCSD Cancer Center have new evidence that a type of immune system cell thought to be part of the first line of defense against breast cancer may also help promote its spread. They have found that when these cells, known as lymphocytes, make an inflammatory protein called RANKL (RANK ligand), breast cancer is more likely to spread to the lungs.
Apr 22, 2009 - 4:00:00 AM
|
Latest Research
Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies
DENVER, Colorado and TUSTIN, Calif., April 21, 2009--Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies. One study confirms the anti-tumor effects and immune stimulating ability of a fully human anti-PS antibody and the other demonstrates the ability of a second fully human anti-PS antibody to stimulate development of a critical component of the adaptive immune system.
Apr 21, 2009 - 4:00:00 AM
|
Latest Research
High levels of PEA-15 shrink breast cancer tumors
DENVER - Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.
Apr 20, 2009 - 4:00:00 AM
|
Latest Research
Pregnancy hormone hCG protects against breast cancer even in short-term treatments
One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age. Studies out of Fox Chase Cancer Center have linked this protective effect to the presence of human chorionic gonadotropin (hCG), a hormone produced by the placenta to maintain the early stages of pregnancy. Their findings in an animal model of breast cancer showed that rats exposed to hCG over a 21 day period (the length of rat pregnancy), are far less likely to develop breast cancer when exposed to a known carcinogen.
Apr 20, 2009 - 4:00:00 AM
|
Latest Research
Genetic variants predict recurrence of bladder cancer, patient survival
DENVER - Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy.
Apr 20, 2009 - 4:00:00 AM
|
Latest Research
Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
DENVER - A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report. With further testing of these drugs that are from classes of pharmaceuticals already used in patients, the Mayo research may lead to new treatment opportunities for patients with pancreatic cancer, which is extremely difficult to treat.
Apr 19, 2009 - 4:00:00 AM
|
Latest Research
Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
DENVER - A national team of researchers led by Mayo Clinic has found that patients with chronic lymphocytic leukemia (CLL) are more likely to have similar DNA changes or variants in up to six genes, compared to people who do not have the cancer.
Apr 19, 2009 - 4:00:00 AM
|
Latest Research
:
Cancer
Herb-based anti-cancer chemical made in lab
Washington, April 16 - Club moss Lycopodium serratum is a flowerless plant whose potent brew of alkaloids, which could have anti-cancer properties and may combat memory loss, have drawn considerable scientific and medical interest. Now scientists have made one of the alkaloids in a lab, in quantity sufficient for use.
Apr 16, 2009 - 1:32:57 PM
|
Latest Research
Leading cancer organizations team up on tumor-promoting protein
An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation's two premier cancer research organizations.
Apr 16, 2009 - 4:00:00 AM
|
Latest Research
Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
CHICAGO - An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer. Thoracic surgeons at Rush University Medical Center are researching the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is designed to kill cancer cells without harming normal cells. Rush is one of only five hospitals in Illinois offering the vaccine.
Apr 6, 2009 - 4:00:00 AM
|
Latest Research
Naturally fluorescent molecules may serve as cancer biomarker
Excess amounts of a naturally fluorescent molecule found in all living cells could serve as a natural biomarker for cancer, according to bioengineers.
Apr 2, 2009 - 4:00:00 AM
|
Latest Research
:
Cancer
:
Therapy
Bionic Nose to Detect Cancers
Washington, March 31 - Both cancer cells and chemicals used in bombs evade detection because they are present in very small quantities. But now a new method being developed can detect them by amplifying near invisible traces of biomarkers in cancer, materials in explosives or pollutants in water.
Mar 31, 2009 - 12:12:47 PM
|
Latest Research
What's in your water?: Disinfectants create toxic by-products
Although perhaps the greatest public health achievement of the 20th century was the disinfection of water, a recent study now shows that the chemicals used to purify the water we drink and use in swimming pools react with organic material in the water yielding toxic consequences.
Mar 31, 2009 - 4:00:00 AM
|
Latest Research
Montana State grad's work helps diagnose skin cancer without a biopsy
BOZEMAN -- A recent Montana State University master's graduate is working with doctors at Vanderbilt Medical Center in Tennessee to build a handheld laser microscope that could someday reduce the number of biopsies needed to diagnose skin cancer.
Mar 30, 2009 - 4:00:00 AM
|
Latest Research
Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists
Two researchers from NYU School of Medicine have been named Early Career Scientists by the Howard Hughes Medical Institute (HHMI). The honorees, Iannis Aifantis, Ph.D. associate professor of pathology, co-director of the Cancer Stem Cell Program at the NYU Cancer Institute and Jeremy S. Dasen Ph.D., assistant professor of physiology and neuroscience at NYU School of Medicine are among 50 of the nation's top scientists being honored by HHMI under this new initiative to establish, develop and grow unique research programs.
Mar 26, 2009 - 4:00:00 AM
|
Latest Research
New book chronicles the journeys of women physicians and scientists to fighting cancer
HOUSTON - Just more than one year after it was created, the office of Women Faculty Programs at The University of Texas M. D. Anderson Cancer Center has introduced a collection of essays by leading women faculty aimed at inspiring generations of women scientists to come.
Mar 23, 2009 - 4:00:00 AM
|
Latest Research
:
Cancer
New RNA treatment can shrink cancers
Washington, March 20 - A newly-identified type of microRNA could tackle aggressive cancers by helping to kill off their cells.
Mar 20, 2009 - 3:23:55 PM
|
Latest Research
Lung cancer: Molecular scissors determine therapy effectiveness
In the past few years, a number of anti-cancer drugs have been developed which are directed selectively against specific key molecules of tumor cells. Among these is an antibody called cetuximab, which attaches to a protein molecule that is found in large amounts on the surface of many types of cancer cells. When this surface molecule, called epidermal growth factor receptor, or EGF-R for short, is blocked by cetuximab, the cancer cell receives less signals stimulating cell division.
Mar 17, 2009 - 4:00:00 AM
|
Latest Research
Rearrangements of multifunctional genes cause cancer in children and young people
A doctoral thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden, shows that three genes that lie behind a number of malignant tumour diseases are normally involved in several fundamental processes in the cell. This may be the reason that the tumours arise early in life and principally affect children and young people.
Mar 10, 2009 - 4:00:00 AM
|
Latest Research
Immune-based drug approved in Europe for pediatric cancer patients
HOUSTON ? The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer. The approval is based on clinical studies led by researchers at The University of Texas M. D. Anderson Cancer Center and a national co-operative group.
Mar 10, 2009 - 4:00:00 AM
|
Latest Research
New staging technique might save bladders in some bladder cancer patients
MAYWOOD, Ill. -- Pathologists today (March 9, 2009) reported encouraging results from a new technique to increase the accuracy of staging bladder cancer tumors that could reduce the need to remove bladders from some patients.
Mar 9, 2009 - 4:00:00 AM
|
Latest Research
MRI and PET/CT improve cervical cancer patient's chances for optimal treatment
Pretreatment MRI and PET/CT for cervical cancer may direct more women to optimal therapy choices and spare many women potential long-term morbidity and complications of trimodality therapy (surgery followed by chemoradiation), according to a study performed at the Institute for Technology Assessment in Boston, MA.
Mar 4, 2009 - 5:00:00 AM
|
Latest Research
UT nanoscientist gets $7 million DoD Innovator Award for breast cancer research
Mauro Ferrari, Ph.D., a nanomedicine scientist at The University of Texas Health Science Center at Houston and The University of Texas M. D. Anderson Cancer Center, has received a five-year, $7 million Innovator Award from the U.S. Department of Defense (DoD) Breast Cancer Research Program to develop a targeted new delivery system for breast cancer drugs.
.
If this new approach proves successful, it could increase the efficiency of drug delivery by concentrating more drug at the site of a tumor. A more efficient drug delivery system has the potential to reduce side effects associated with these drugs.
Mar 3, 2009 - 5:00:00 AM
|
Latest Research
:
Cancer
:
Prostate Cancer
Oncologists present test to predict survival in castration-resistant prostate cancer patients
Dana-Farber Cancer Institute (DFCI) and Source MDx today
announced that Source MDx’s whole blood RNA transcript-based Precision Profiles™ diagnostic test predicted survival in men with castration-resistant prostate cancer (CRPC). In a study of 62 CRPC patients, the model separated patients into a high risk group (survival less than 2.2 years) and a low risk group (survival greater than 2.2 years) (log rank p=0.00083).
Mar 1, 2009 - 9:13:14 AM
|
Latest Research
:
Cancer
:
Skin
:
Melanoma
Compounds extracted from vegetables help to inhibit melanoma
Compounds extracted from green vegetables such as broccoli and cabbage could be a potent drug against melanoma, according to cancer researchers. Tests on mice suggest that these compounds, when combined with selenium, target tumors more safely and effectively than conventional therapy.
Mar 1, 2009 - 9:00:20 AM
|
Latest Research
:
Cancer
:
Therapy
Anti- cancer gene discovered- new strategy for treatment?
Starting with the tiny fruit fly, and then moving into mouse and human patients, researchers at VIB connected to the Center for Human Genetics (K.U. Leuven) showed that the same gene suppresses cancer in all three. Reciprocally, switching off the gene leads to cancer. The scientists think there is a good chance that the gene can be switched on again with a drug. They report their findings in the reputed scientific journal PLoS Biology.
Feb 25, 2009 - 12:48:17 AM
|
Latest Research
:
Cancer
:
Prostate Cancer
PSA levels appear to be predictive of three year prostate cancer risk in African-American men
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Feb 25, 2009 - 12:43:24 AM
|
Latest Research
Case Western Reserve researchers looking at light-induced toxins in air and water
Is the air we breathe on a daily basis slowly killing us?
Feb 16, 2009 - 5:00:00 AM
|
Latest Research
Ronald P. Stanton gives $50 million toward cancer care at NewYork-Presbyterian Hospital
NEW YORK (Feb. 11, 2009) -- NewYork-Presbyterian Hospital announced today that it has received a $50 million commitment from noted business leader, longtime supporter and Hospital Trustee Ronald P. Stanton. The gift will establish the Ronald P. Stanton Clinical Cancer Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, strengthening and expanding the Hospital's ability to provide patients with the very best cancer care.
Feb 11, 2009 - 5:00:00 AM
|
Latest Research
:
Cancer
:
Testicular Cancer
Marijuana use increases risk of testicular cancer
Frequent and/or long-term marijuana use may significantly increase a man's risk of developing the most aggressive type of testicular cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center. The study results were published online Feb. 9 in the journal Cancer.
Feb 9, 2009 - 12:21:51 PM
|
Latest Research
:
Cancer
:
Skin
:
Melanoma
MicroRNA responsible for aggressiveness of metastatic melanoma cell lines
Scientists have long wondered how melanoma cells travel from primary tumors on the surface of the skin to the brain, liver and lungs, where they become more aggressive, resistant to therapy, and deadly. Now, scientists from NYU Langone Medical Center have identified the possible culprit—a short strand of RNA called microRNA (miRNA) that is over-expressed in metastatic melanoma cell lines and tissues.
Feb 9, 2009 - 12:10:26 PM
|
|
|
|
|
